Real-world effectiveness and predictors of sustained virological response with all-oral therapy in 21,242 hepatitis C genotype-1 patients

被引:61
作者
Backus, Lisa, I [1 ]
Belperio, Pamela S. [1 ]
Shahoumian, Troy A. [1 ]
Loomis, Timothy P. [1 ]
Mole, Larry A. [1 ]
机构
[1] Dept Vet Affairs, Populat Hlth Serv, Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA
关键词
TREATMENT HCV RNA; 1; INFECTION; VIRUS-INFECTION; SOFOSBUVIR; RIBAVIRIN; PREVALENCE; CIRRHOSIS; ABT-450/R-OMBITASVIR; LEDIPASVIR; SIMEPREVIR;
D O I
10.3851/IMP3117
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Predictors of sustained virological response (SVR) to all-oral HCV regimens can inform nuanced treatment decisions. We evaluated effectiveness and identified predictors of SVR for ledipasvir/sofosbuvir +/- ribavirin (LDV/SOF +/- RBV) and ombitasvir/paritaprevir/ritonavir + dasabuvir (OPrD) +/- RBV in patients treated in routine practice.& para;& para;Methods: Observational, intent-to-treat cohort of 21,142 genotype-1 patients initiating 8 or 12 weeks of LDV/SOF +/- RBV or 12 weeks of OPrD +/- RBV at any Veterans Affairs facility. Multivariate logistic regression models were constructed to model SVR and identify predictors.& para;& para;Results: SVR was 91.2% (9,781/10,720) for LDV/SOF, 89.6% (3,266/3,646) for LDV/SOF+RBV, 91.7% (1,197/1,306) for OPrD and 87.8% (3,365/3,832) for OPrD+RBV. For LDV/SOF +/- RBV, reduced odds of SVR occurred in African-Americans (0.80, 95% CI 0.70, 0.92, P<0.001), body mass index (BMI)<25 (0.77, 95% CI 0.66, 0.90, P<0.001), BML >= 30 (0.77, 95% CI 0.67, 0.89, P<0.001), proton pump inhibitors (PPIs; 0.81, 95% CI 0.71, 0.92, P<0.001), decompensated liver disease (0.58, 95% CI 0.45, 0.74, P<0.001) and FIB4>3.25 (0.60, 95% CI 0.53, 0.69, P<0.001). For OPrD +/- RBV, FIB-4>3.25 negatively predicted SVR (0.72, 95% CI 0.59, 0.88, P<0.001). Detectable 4-week on-treatment HCV RNA >= 15 IU/ml reduced SVR odds for both regimens (LDV/SOF +/- RBV OR 0.49, 95% CI 0.41, 0.58, P<0.001; OPrD +/- RBV OR 0.38, 95% CI 0.29, 0.50, P<0.001). Receipt of OPrD+RBV compared to LDV/SOF reduced odds of SVR (OR 0.70, 95% CI 0.62, 0.80, P<0.001). Mental health diagnosis did not impact likelihood of SVR.& para;& para;Conclusions: The diversity and size of this cohort allowed for extensive examination of regimen-specific predictors of SVR. FIB-4>3.25 and detectable 4-week on-treatment HCV RNA had the greatest negative impact. African-American race, low or high BMI, and PPIs negatively impacted odds of SVR for LDV/SOF +/- RBV. Mental health diagnoses did not.
引用
收藏
页码:481 / 493
页数:13
相关论文
共 24 条
[1]   Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection [J].
Afdhal, Nezam ;
Zeuzem, Stefan ;
Kwo, Paul ;
Chojkier, Mario ;
Gitlin, Norman ;
Puoti, Massimo ;
Romero-Gomez, Manuel ;
Zarski, Jean-Pierre ;
Agarwal, Kosh ;
Buggisch, Peter ;
Foster, Graham R. ;
Braeu, Norbert ;
Buti, Maria ;
Jacobson, Ira M. ;
Subramanian, G. Mani ;
Ding, Xiao ;
Mo, Hongmei ;
Yang, Jenny C. ;
Pang, Phillip S. ;
Symonds, William T. ;
McHutchison, John G. ;
Muir, Andrew J. ;
Mangia, Alessandra ;
Marcellin, Patrick .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (20) :1889-1898
[2]   Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection [J].
Afdhal, Nezam ;
Reddy, K. Rajender ;
Nelson, David R. ;
Lawitz, Eric ;
Gordon, Stuart C. ;
Schiff, Eugene ;
Nahass, Ronald ;
Ghalib, Reem ;
Gitlin, Norman ;
Herring, Robert ;
Lalezari, Jacob ;
Younes, Ziad H. ;
Pockros, Paul J. ;
Di Bisceglie, Adrian M. ;
Arora, Sanjeev ;
Subramanian, G. Mani ;
Zhu, Yanni ;
Dvory-Sobol, Hadas ;
Yang, Jenny C. ;
Pang, Phillip S. ;
Symonds, William T. ;
McHutchison, John G. ;
Muir, Andrew J. ;
Sulkowski, Mark ;
Kwo, Paul .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (16) :1483-1493
[3]   Impact of Obesity on the Bioavailability of Peginterferon-α2a and Ribavirin and Treatment Outcome for Chronic Hepatitis C Genotype 2 or 3 [J].
Alsio, Asa ;
Rembeck, Karolina ;
Askarieh, Galia ;
Christensen, Peer Brehm ;
Farkkila, Martti ;
Langeland, Nina ;
Buhl, Mads Rauning ;
Pedersen, Court ;
Morch, Kristine ;
Haagmans, Bart L. ;
Nasic, Salmir ;
Westin, Johan ;
Hellstrand, Kristoffer ;
Norkrans, Gunnar ;
Lagging, Martin .
PLOS ONE, 2012, 7 (05)
[4]   Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis [J].
Aqel, Bashar A. ;
Pungpapong, Surakit ;
Leise, Michael ;
Werner, K. Tuesday ;
Chervenak, Amy E. ;
Watt, Kymberly D. ;
Murphy, Jennifer L. ;
Ryland, Kristen ;
Keaveny, Andrew P. ;
McLemore, Ryan ;
Vargas, Hugo E. .
HEPATOLOGY, 2015, 62 (04) :1004-1012
[5]   The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 [J].
Armstrong, Gregory L. ;
Wasley, Annemarie ;
Simard, Edgar P. ;
McQuillan, Geraldine M. ;
Kuhnert, Wendi L. ;
Alter, Miriam J. .
ANNALS OF INTERNAL MEDICINE, 2006, 144 (10) :705-714
[6]   Comparative effectiveness of ledipasvir/sofosbuvir±ribavirin vs. ombitasvir/paritaprevir/ritonavir plus dasabuvir±ribavirin in 6961 genotype 1 patients treated in routine medical practice [J].
Backus, L. I. ;
Belperio, P. S. ;
Shahoumian, T. A. ;
Loomis, T. P. ;
Mole, L. A. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2016, 44 (04) :400-410
[7]   Hepatitis C Virus Screening and Prevalence Among US Veterans in Department of Veterans Affairs Care [J].
Backus, Lisa I. ;
Belperio, Pamela S. ;
Loomis, Timothy P. ;
Yip, Gale H. ;
Mole, Larry A. .
JAMA INTERNAL MEDICINE, 2013, 173 (16) :1549-1552
[8]   Clinical Case Registries: Simultaneous Local and National Disease Registries for Population Quality Management [J].
Backus, Lisa I. ;
Gavrilov, Sergey ;
Loomis, Timothy P. ;
Halloran, James P. ;
Phillips, Barbara R. ;
Belperio, Pamela S. ;
Mole, Larry A. .
JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION, 2009, 16 (06) :775-783
[9]   Blood Tests to Diagnose Fibrosis or Cirrhosis in Patients With Chronic Hepatitis C Virus Infection A Systematic Review [J].
Chou, Roger ;
Wasson, Ngoc .
ANNALS OF INTERNAL MEDICINE, 2013, 158 (11) :807-+
[10]   Investigation of NS3 Protease Resistance-Associated Variants and Phenotypes for the Prediction of Treatment Response to HCV Triple Therapy [J].
Dietz, Julia ;
Rupp, Daniel ;
Susser, Simone ;
Vermehren, Johannes ;
Peiffer, Kai-Henrik ;
Filmann, Natalie ;
Bon, Dimitra ;
Kuntzen, Thomas ;
Mauss, Stefan ;
Grammatikos, Georgios ;
Perner, Dany ;
Berkowski, Caterina ;
Herrmann, Eva ;
Zeuzem, Stefan ;
Bartenschlager, Ralf ;
Sarrazin, Christoph .
PLOS ONE, 2016, 11 (06)